Intrinsic multi-specific liabilities: Have we sufficiently built and leveraged cross‑platform learnings to understand how different multi‑specific formats intrinsically drive instability? 

Early screening and platform gaps: How can we close the gap in early developability screening to deliver predictive, scalable insights that translate to formulation and manufacturing success? 

Colloidal instability at relevant concentrations: How do we effectively manage colloidal instability at high concentration, including self‑association, viscosity, and phase behaviors such as LLPS and opalescence? 

Choice of excipients: What excipient strategies can robustly mitigate aggregation, particle formation, and viscosity while remaining practical and scalable for development? 

Phase appropriate development strategy with end to end considerations: How balance speed, robustness, device compatibility, and comparability when selecting the DP presentation?